Mark Wickens
- Internal Medicine top 1%
- Oncology top 0.5%
- PARP inhibition in cancer therapy 4
- Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment 4
- Cancer Research top 2%
-
- Antiplatelet Therapy and Cardiovascular Diseases 4
-
- BRCA gene mutations in cancer 3
-
- Inflammatory mediators and NSAID effects 3
- Pharmacology and Obesity Treatment 2
-
- Eicosanoids and Hypertension Pharmacology 2
-
- Neuropeptides and Animal Physiology 2
- Co-authors
- James CarmichaelMichael FriedländerJeffrey N. WeitzelM. William AudehAndrew TuttRita K. SchmutzlerUrsula A. MatulonisKatherine M. Bell‐McGuinn
- Journals
- European Heart Journal (2 papers)The Lancet (2 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Mark Wickens
14 papers receiving 4.5k citations
Hit Papers
Peers
Comparison fields: 5 of 99
- Internal Medicine 384
- Oncology 2.7k
- Reproductive Medicine 694
- Cancer Research 720
- Cardiology and Cardiovascular Medicine 1.0k
Countries citing papers authored by Mark Wickens
This map shows the geographic impact of Mark Wickens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wickens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wickens more than expected).
Fields of papers citing papers by Mark Wickens
This network shows the impact of papers produced by Mark Wickens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wickens. The network helps show where Mark Wickens may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Wickens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 378 | |
| 2 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialbreakdown → | 2010 | 1286 |
| 3 | 2010 | 26 | |
| 4 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialbreakdown → | 2010 | 1742 |
| 5 | PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS | 2010 | 21 |
| 6 | 2009 | 49 | |
| 7 | 2007 | 372 | |
| 8 | 2007 | 1 | |
| 9 | Abstract 3292: AZD6140 Exerts Greater Inhibition of Platelet Aggregation than Clopidogrel in Patients with Stable Atherosclerotic Disease or Unstable Coronary Disease | 2006 | 2 |
| 10 | 2006 | 21 | |
| 11 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinbreakdown → | 2006 | 575 |
| 12 | Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. | 2001 | 27 |
| 13 | 2000 | 32 | |
| 14 | 1995 | 101 |
About Mark Wickens
Mark Wickens is a scholar working on Reproductive Medicine, Pharmacology, Biochemistry, Internal Medicine and Cardiology and Cardiovascular Medicine, having authored 14 papers that have together received 4.6k indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (4 papers), Ovarian cancer diagnosis and treatment (4 papers), PARP inhibition in cancer therapy (4 papers), BRCA gene mutations in cancer (3 papers), Inflammatory mediators and NSAID effects (3 papers), Pharmacology and Obesity Treatment (2 papers), Eicosanoids and Hypertension Pharmacology (2 papers) and Neuropeptides and Animal Physiology (2 papers). The work is most often cited by research in Internal Medicine (384 citations), Oncology (2.7k citations), Reproductive Medicine (694 citations), Cancer Research (720 citations) and Cardiology and Cardiovascular Medicine (1.0k citations). Mark Wickens has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include James Carmichael, Michael Friedländer, Jeffrey N. Weitzel, M. William Audeh, Andrew Tutt, Rita K. Schmutzler, Ursula A. Matulonis, Katherine M. Bell‐McGuinn, Håkan Emanuelsson and Steen Husted. Their work appears in journals such as European Heart Journal, The Lancet, Journal of Clinical Oncology, British Journal of Cancer and British Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.